Poor
Not Aligned
Patient Risk:
Low
Summary
Most claims concern FDA pediatric exclusivity/marketing exclusivity extensions, which are not addressed in the INFUVITE PEDIATRIC prescribing information excerpts provided. No AI statements were verifiable against the supplied label content.
Category Scores
Accurate Statements
Unsupported Statements
The FDA can extend the marketing exclusivity for certain drugs by 6 months to encourage pediatric studies.
Not supported by the provided INFUVITE PEDIATRIC prescribing information excerpts; label content supplied does not discuss marketing/pediatric exclusivity extensions.
The 6-month pediatric exclusivity extension is tied to the sponsor submitting required pediatric assessments under the FDA Written Request process.
Not supported by the provided INFUVITE PEDIATRIC prescribing information excerpts.
The pediatric exclusivity extension can apply even when the drug already has other exclusivity types, as long as it meets the program rules.
Not supported by the provided INFUVITE PEDIATRIC prescribing information excerpts.
Pediatric exclusivity is not automatic for all drugs.
Not supported by the provided INFUVITE PEDIATRIC prescribing information excerpts.
Pediatric exclusivity generally applies only to eligible products with qualifying exclusivity that can be extended.
Not supported by the provided INFUVITE PEDIATRIC prescribing information excerpts.
Eligible products must have met the pediatric study requirements under FDA’s pediatric exclusivity framework.
Not supported by the provided INFUVITE PEDIATRIC prescribing information excerpts.
Pediatric exclusivity extends certain existing marketing exclusivities.
Not supported by the provided INFUVITE PEDIATRIC prescribing information excerpts.
The pediatric exclusivity 6-month add-on relates to the drug’s exclusivity term rather than regulatory approval itself.
Not supported by the provided INFUVITE PEDIATRIC prescribing information excerpts.
Eligibility for the 6-month pediatric extension depends on the type of exclusivity and whether the sponsor’s pediatric submission satisfies FDA’s Written Request requirements.
Not supported by the provided INFUVITE PEDIATRIC prescribing information excerpts.
Sponsors must submit pediatric information that corresponds to an FDA-issued Written Request for pediatric studies.
Not supported by the provided INFUVITE PEDIATRIC prescribing information excerpts.
If the Written Request is fulfilled, the pediatric exclusivity extension may be granted.
Not supported by the provided INFUVITE PEDIATRIC prescribing information excerpts.
The pediatric exclusivity extension extends the relevant exclusivity by 6 months.
Not supported by the provided INFUVITE PEDIATRIC prescribing information excerpts.
The extension is 6 months added to the existing marketing exclusivity period for the eligible drug based on FDA’s pediatric exclusivity determination.
Not supported by the provided INFUVITE PEDIATRIC prescribing information excerpts.
Eligibility depends on whether the drug has an exclusivity term that can be extended under the program.
Not supported by the provided INFUVITE PEDIATRIC prescribing information excerpts.
Eligibility depends on whether the sponsor fulfills the FDA Written Request with the required pediatric studies/submissions.
Not supported by the provided INFUVITE PEDIATRIC prescribing information excerpts.
A specific drug’s pediatric exclusivity extension can be verified through FDA’s pediatric exclusivity listings and related FDA materials tied to that drug’s exclusivity status.
Not supported by the provided INFUVITE PEDIATRIC prescribing information excerpts.
Contradictions
Important Omissions
INFUVITE PEDIATRIC-specific prescribing information claims relevant to the audit context (e.g., indication wording, dosing/administration instructions, contraindications, warnings/precautions, drug interactions, adverse reactions) were not addressed in the AI statements provided.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The provided AI statements do not describe patient dosing, contraindications, or clinical safety risks for INFUVITE PEDIATRIC; however, they are largely unrelated to the supplied product label content.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Claims focus on FDA pediatric exclusivity/marketing exclusivity mechanisms, which are not contained in the provided INFUVITE PEDIATRIC prescribing information excerpts.
Suggested Improvement
Limit statements to what is present in the INFUVITE PEDIATRIC label excerpts (e.g., indication for prevention of vitamin deficiency in pediatric patients up to 11 years receiving parenteral nutrition; administration/dilution and key warnings/precautions/interactions) or provide the correct label section/source that addresses exclusivity and Written Request mechanisms.